Cardiac regenerative medicine

研究成果: Article

19 引用 (Scopus)

抄録

Severe heart failure is associated with damage to the myocardium that is irreversible with current medical therapies. Recent experimental and clinical studies, however, have opened the possibility of solving many of the associated problems, making this an exciting and tangible goal. There are many potential cell sources for regenerative cardiac medicine, including bone marrow stem cells, endothelial progenitor cells, skeletal myocytes, adult cardiac stem cells, and embryonic stem (ES) cells. Although ES cells are highly proliferative and suitable for mass production, they are not autologous, and an efficient protocol is yet to be established to ensure selective cardiomyocyte induction. Recent studies have successfully established inducible pluripotent stem (iPS) cells from mouse and human fibroblasts by the gene transfer of 4 transcription factors that are strongly expressed in ES cells: Oct3/4, Sox2, Klf4 and c-Myc. iPS cells can differentiate into all 3 germ layer-derived cells and are syngeneic, indicating that they can become an ideal cell source for regenerative medicine. Despite these successes, the accumulating evidence from fields as diverse as developmental biology, stem cell biology and tissue engineering must be integrated to achieve the full potential of cardiac regenerative medicine.

元の言語English
ジャーナルCirculation Journal
72
発行部数SUPPL. A
DOI
出版物ステータスPublished - 2008

Fingerprint

Regenerative Medicine
Embryonic Stem Cells
Pluripotent Stem Cells
Stem Cells
Cell Engineering
Germ Layers
Developmental Biology
Adult Stem Cells
Skeletal Muscle Fibers
Tissue Engineering
Cardiac Myocytes
Bone Marrow Cells
Cell Biology
Myocardium
Transcription Factors
Heart Failure
Fibroblasts
Genes
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

これを引用

Cardiac regenerative medicine. / Yuasa, Shinsuke; Fukuda, Keiichi.

:: Circulation Journal, 巻 72, 番号 SUPPL. A, 2008.

研究成果: Article

@article{805a356c5a1342eba11bb4177d7d8d8a,
title = "Cardiac regenerative medicine",
abstract = "Severe heart failure is associated with damage to the myocardium that is irreversible with current medical therapies. Recent experimental and clinical studies, however, have opened the possibility of solving many of the associated problems, making this an exciting and tangible goal. There are many potential cell sources for regenerative cardiac medicine, including bone marrow stem cells, endothelial progenitor cells, skeletal myocytes, adult cardiac stem cells, and embryonic stem (ES) cells. Although ES cells are highly proliferative and suitable for mass production, they are not autologous, and an efficient protocol is yet to be established to ensure selective cardiomyocyte induction. Recent studies have successfully established inducible pluripotent stem (iPS) cells from mouse and human fibroblasts by the gene transfer of 4 transcription factors that are strongly expressed in ES cells: Oct3/4, Sox2, Klf4 and c-Myc. iPS cells can differentiate into all 3 germ layer-derived cells and are syngeneic, indicating that they can become an ideal cell source for regenerative medicine. Despite these successes, the accumulating evidence from fields as diverse as developmental biology, stem cell biology and tissue engineering must be integrated to achieve the full potential of cardiac regenerative medicine.",
keywords = "Cardiomyocyte, Cell differentiation, Cell transplantation, Stem cell, Tissue engineering",
author = "Shinsuke Yuasa and Keiichi Fukuda",
year = "2008",
doi = "10.1253/circj.CJ-08-0378",
language = "English",
volume = "72",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "SUPPL. A",

}

TY - JOUR

T1 - Cardiac regenerative medicine

AU - Yuasa, Shinsuke

AU - Fukuda, Keiichi

PY - 2008

Y1 - 2008

N2 - Severe heart failure is associated with damage to the myocardium that is irreversible with current medical therapies. Recent experimental and clinical studies, however, have opened the possibility of solving many of the associated problems, making this an exciting and tangible goal. There are many potential cell sources for regenerative cardiac medicine, including bone marrow stem cells, endothelial progenitor cells, skeletal myocytes, adult cardiac stem cells, and embryonic stem (ES) cells. Although ES cells are highly proliferative and suitable for mass production, they are not autologous, and an efficient protocol is yet to be established to ensure selective cardiomyocyte induction. Recent studies have successfully established inducible pluripotent stem (iPS) cells from mouse and human fibroblasts by the gene transfer of 4 transcription factors that are strongly expressed in ES cells: Oct3/4, Sox2, Klf4 and c-Myc. iPS cells can differentiate into all 3 germ layer-derived cells and are syngeneic, indicating that they can become an ideal cell source for regenerative medicine. Despite these successes, the accumulating evidence from fields as diverse as developmental biology, stem cell biology and tissue engineering must be integrated to achieve the full potential of cardiac regenerative medicine.

AB - Severe heart failure is associated with damage to the myocardium that is irreversible with current medical therapies. Recent experimental and clinical studies, however, have opened the possibility of solving many of the associated problems, making this an exciting and tangible goal. There are many potential cell sources for regenerative cardiac medicine, including bone marrow stem cells, endothelial progenitor cells, skeletal myocytes, adult cardiac stem cells, and embryonic stem (ES) cells. Although ES cells are highly proliferative and suitable for mass production, they are not autologous, and an efficient protocol is yet to be established to ensure selective cardiomyocyte induction. Recent studies have successfully established inducible pluripotent stem (iPS) cells from mouse and human fibroblasts by the gene transfer of 4 transcription factors that are strongly expressed in ES cells: Oct3/4, Sox2, Klf4 and c-Myc. iPS cells can differentiate into all 3 germ layer-derived cells and are syngeneic, indicating that they can become an ideal cell source for regenerative medicine. Despite these successes, the accumulating evidence from fields as diverse as developmental biology, stem cell biology and tissue engineering must be integrated to achieve the full potential of cardiac regenerative medicine.

KW - Cardiomyocyte

KW - Cell differentiation

KW - Cell transplantation

KW - Stem cell

KW - Tissue engineering

UR - http://www.scopus.com/inward/record.url?scp=52949151845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52949151845&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-08-0378

DO - 10.1253/circj.CJ-08-0378

M3 - Article

C2 - 18772528

AN - SCOPUS:52949151845

VL - 72

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - SUPPL. A

ER -